Antimalarial drugs inhibit the replication of SARS-CoV-2 : An in vitro evaluation
Copyright © 2020 Elsevier Ltd. All rights reserved..
In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. African countries see slower dynamic of COVID-19 cases and deaths. One of the assumptions that may explain this later emergence in Africa, and more particularly in malaria endemic areas, would be the use of antimalarial drugs. We investigated the in vitro antiviral activity against SARS-CoV-2 of several antimalarial drugs. Chloroquine (EC50 = 2.1 μM and EC90 = 3.8 μM), hydroxychloroquine (EC50 = 1.5 μM and EC90 = 3.0 μM), ferroquine (EC50 = 1.5 μM and EC90 = 2.4 μM), desethylamodiaquine (EC50 = 0.52 μM and EC90 = 1.9 μM), mefloquine (EC50 = 1.8 μM and EC90 = 8.1 μM), pyronaridine (EC50 = 0.72 μM and EC90 = 0.75 μM) and quinine (EC50 = 10.7 μM and EC90 = 38.8 μM) showed in vitro antiviral effective activity with IC50 and IC90 compatible with drug oral uptake at doses commonly administered in malaria treatment. The ratio Clung/EC90 ranged from 5 to 59. Lumefantrine, piperaquine and dihydroartemisinin had IC50 and IC90 too high to be compatible with expected plasma concentrations (ratio Cmax/EC90 < 0.05). Based on our results, we would expect that countries which commonly use artesunate-amodiaquine or artesunate-mefloquine report fewer cases and deaths than those using artemether-lumefantrine or dihydroartemisinin-piperaquine. It could be necessary now to compare the antimalarial use and the dynamics of COVID-19 country by country to confirm this hypothesis.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
---|---|
Enthalten in: |
Travel medicine and infectious disease - 37(2020) vom: 15. Sept., Seite 101873 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gendrot, Mathieu [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antimalarial drugs |
---|
Anmerkungen: |
Date Completed 29.10.2020 Date Revised 12.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.tmaid.2020.101873 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM314884998 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM314884998 | ||
003 | DE-627 | ||
005 | 20231225153714.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.tmaid.2020.101873 |2 doi | |
028 | 5 | 2 | |a pubmed24n1049.xml |
035 | |a (DE-627)NLM314884998 | ||
035 | |a (NLM)32916297 | ||
035 | |a (PII)S1477-8939(20)30369-0 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Gendrot, Mathieu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Antimalarial drugs inhibit the replication of SARS-CoV-2 |b An in vitro evaluation |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.10.2020 | ||
500 | |a Date Revised 12.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
520 | |a In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. African countries see slower dynamic of COVID-19 cases and deaths. One of the assumptions that may explain this later emergence in Africa, and more particularly in malaria endemic areas, would be the use of antimalarial drugs. We investigated the in vitro antiviral activity against SARS-CoV-2 of several antimalarial drugs. Chloroquine (EC50 = 2.1 μM and EC90 = 3.8 μM), hydroxychloroquine (EC50 = 1.5 μM and EC90 = 3.0 μM), ferroquine (EC50 = 1.5 μM and EC90 = 2.4 μM), desethylamodiaquine (EC50 = 0.52 μM and EC90 = 1.9 μM), mefloquine (EC50 = 1.8 μM and EC90 = 8.1 μM), pyronaridine (EC50 = 0.72 μM and EC90 = 0.75 μM) and quinine (EC50 = 10.7 μM and EC90 = 38.8 μM) showed in vitro antiviral effective activity with IC50 and IC90 compatible with drug oral uptake at doses commonly administered in malaria treatment. The ratio Clung/EC90 ranged from 5 to 59. Lumefantrine, piperaquine and dihydroartemisinin had IC50 and IC90 too high to be compatible with expected plasma concentrations (ratio Cmax/EC90 < 0.05). Based on our results, we would expect that countries which commonly use artesunate-amodiaquine or artesunate-mefloquine report fewer cases and deaths than those using artemether-lumefantrine or dihydroartemisinin-piperaquine. It could be necessary now to compare the antimalarial use and the dynamics of COVID-19 country by country to confirm this hypothesis | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Antimalarial drugs | |
650 | 4 | |a Antiviral | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a In vitro | |
650 | 4 | |a SARS-CoV-2 | |
650 | 7 | |a Antimalarials |2 NLM | |
700 | 1 | |a Andreani, Julien |e verfasserin |4 aut | |
700 | 1 | |a Boxberger, Manon |e verfasserin |4 aut | |
700 | 1 | |a Jardot, Priscilla |e verfasserin |4 aut | |
700 | 1 | |a Fonta, Isabelle |e verfasserin |4 aut | |
700 | 1 | |a Le Bideau, Marion |e verfasserin |4 aut | |
700 | 1 | |a Duflot, Isabelle |e verfasserin |4 aut | |
700 | 1 | |a Mosnier, Joel |e verfasserin |4 aut | |
700 | 1 | |a Rolland, Clara |e verfasserin |4 aut | |
700 | 1 | |a Bogreau, Hervé |e verfasserin |4 aut | |
700 | 1 | |a Hutter, Sébastien |e verfasserin |4 aut | |
700 | 1 | |a La Scola, Bernard |e verfasserin |4 aut | |
700 | 1 | |a Pradines, Bruno |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Travel medicine and infectious disease |d 2003 |g 37(2020) vom: 15. Sept., Seite 101873 |w (DE-627)NLM16457655X |x 1873-0442 |7 nnns |
773 | 1 | 8 | |g volume:37 |g year:2020 |g day:15 |g month:09 |g pages:101873 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tmaid.2020.101873 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 37 |j 2020 |b 15 |c 09 |h 101873 |